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http://dx.doi.org/10.1016/j.stemcr.2016.06.011SUMMARYInduced pluripotent stem cells (iPSCs) represent an innovative source for the standardized in vitro generation of macrophages (M4). We
here describe a robust and efficient protocol to obtain mature and functional M4 from healthy as well as disease-specific murine iPSCs.
With regard tomorphology, surface phenotype, and function, our iPSC-derivedM4 (iPSC-M4) closely resemble their counterparts gener-
ated in vitro from bonemarrow cells. Moreover, when we investigated the feasibility of our differentiation system to serve as a model for
rare congenital diseases associated with M4malfunction, we were able to faithfully recapitulate the pathognomonic defects in GM-CSF
signaling and M4 function present in hereditary pulmonary alveolar proteinosis (herPAP). Thus, our studies may help to overcome the
limitations placed on research into certain rare disease entities by the lack of an adequate supply of disease-specific primary cells, andmay
aid the development of novel therapeutic approaches for herPAP patients.INTRODUCTION
Following the groundbreaking work of Takahashi and
Yamanaka in 2006 (Takahashi et al., 2007; Takahashi and
Yamanaka, 2006), induced pluripotent stem cells (iPSCs)
and their in vitro differentiation into appropriate cell types
or tissues have become a powerful tool to model defined
disease entities as well as to study pathophysiology and
new therapeutic options. With regard to rare diseases,
this approach also allows us to overcome the limited avail-
ability of primary patient cells, a problem still hampering
research in this area to a considerable extent. In this
respect, iPSCs and derived progeny thereof constitute a
valuable and potentially highly standardized source for
the derivation of patient- and disease-specific cells formed-
ical research. This also applies to diseases caused by defects
in progenitor or mature effector cells of the hematopoietic
system, such as lymphocytes (ADA-SCID, X-SCID) (Menon
et al., 2015; Park et al., 2008), granulocytes and myeloid
progenitors (chronic granulomatous disease, juvenile mye-
lomonocytic leukemia) (Gandre-Babbe et al., 2013; Jiang
et al., 2012; Ye et al., 2009), erythrocytes (thalassemias,
sickle cell disease) (Ma et al., 2013; Tubsuwan et al., 2013;292 Stem Cell Reports j Vol. 7 j 292–305 j August 9, 2016 j ª 2016 The Auth
This is an open access article under the CC BY-NC-ND license (http://creativZou et al., 2011), or megakaryocytes (congenital amega-
karyocytic thrombocytopenia) (Hirata et al., 2013), which
all have been successfully recapitulated in vitro utilizing
iPSC-based models.
Macrophages (M4) constitute another highly interesting
cell population in this context. In the past years, our under-
standing of M4 biology has been considerably extended,
especially with regard to tissue-resident populations, such
as osteoclasts, Langerhans’ and Kupffer cells, microglia, or
peritoneal and alveolar M4 (Davies et al., 2013). While
traditionally tissue-resident M4 (TRM) have been regarded
as being continuously replenished from the hematopoietic
stem cells via the intermediate step of peripheral blood
monocytes, this concept now has been challenged for
many tissues. Thus, it has recently been demonstrated
that substantial populationsofTRMsare already seededpre-
natally, exhibit considerable longevity (months to years),
andhave, at least inpart, self-renewal potential (GomezPer-
diguero et al., 2015; Hashimoto et al., 2013). Furthermore, a
high degree of plasticity has been demonstrated forM4 and
TRMs, allowing them to adjust to the specific functional
requirements of the surrounding tissues, e.g., following
organ-specific transplantation (Lavin et al., 2014).or(s).
ecommons.org/licenses/by-nc-nd/4.0/).
For several of these M4 and TRM populations, a direct
and causative role has been identified in the pathophysi-
ology of distinct congenital diseases, including heme
oxygenase 1 deficiency (Kovtunovych et al., 2014), adreno-
leukodystrophy (Biffi et al., 2011; Cartier et al., 2014), auto-
somal recessive osteopetrosis (Neri et al., 2015), Gaucher
disease (Sgambato et al., 2015), andmucopolysaccharidosis
type I (Viana et al., 2016). Another example in this context
is hereditary pulmonary alveolar proteinosis (herPAP),
a life-threatening, rare pulmonary disease caused by
mutations in CSF2RA or CSF2RB encoding the a or b chain
of the granulocyte macrophage colony-stimulating factor
(GM-CSF) receptor, respectively (Suzuki et al., 2008,
2011). These mutations lead to receptor dysfunction and
altered GM-CSF response. As GM-CSF signaling is espe-
cially important for alveolar M4 differentiation, matura-
tion, and function, the corresponding signaling defect
leads to an impaired capacity of alveolar M4 to clear the
alveolar spaces from proteins and phospholipids (Hansen
et al., 2008; Trapnell and Whitsett, 2002). Clinically this
deficiency leads to progressive, life-threatening respiratory
insufficiency and an increased susceptibility to pulmonary
infections. Current treatment options of herPAP are purely
symptomatic and comprise vigorous treatment of infec-
tions and repetitive bilateral whole lung lavage, an invasive
procedure requiring general anesthesia and associated with
significant cardiovascular risks (Trapnell et al., 2003, 2009).
Against this background, we have investigated the feasi-
bility of utilizing murine iPSCs and their hematopoietic
differentiation as a model system for congenital diseases
caused by deficiencies in the M4 compartment. In this re-
gard, and extending the previous work of our group (Pfaff
et al., 2012), we have established a robust protocol allowing
for the differentiation of functional murine M4 from
iPSCs. Using this protocol, we then employed iPSC lines
derived from a mouse model of herPAP to model the GM-
CSF receptor dysfunction pathognomonic of this disease.RESULTS
Generation and Characterization of CD45.1iPSCs
Initial studies were performed with iPSCs generated from
BMlin cells of healthy CD45.1 BL/6 mice (B6.SJL-Ptprca
Pepcb/BoyJ). CD45.1 cells were used for reprogramming
to allow for the easy tracking of respective progeny in clas-
sical C57BL/6-based murine transplant models including
Csf2rb/ PAP mice (Nishinakamura et al., 1995), which
are basedonCD45.2 (C57BL/6J) recipients. Reprogramming
was achievedbytransductionwithapolycistronic third-gen-
eration SIN lentiviral vector expressing the classical ‘‘Yama-
naka’’ factors OCT3/4, KLF4, SOX2, and c-MYC (SIN.Lv.
SFFV.OKSM.dTom) (Kuehle et al., 2014). Several cloneswere generated and, based on its hematopoietic differentia-
tion potential, one clone was selected for further character-
ization. This clone, termed CD45.1(10.3) iPSCs, showed
classical embryonic stem cell (ESC)-like morphology (Fig-
ure 1A) and displayed all major characteristics of pluripo-
tency such as alkaline phosphatase activity (Figure 1B),
endogenous expression of the transcription factors Nanog,
Oct4, and Sox2 (Figures 1C and 1D), expression of the
stage-specific embryonic antigen 1 (SSEA-1; Figure 1E), and,
most importantly, formation of teratomas that comprised
tissues of all three embryonic germ layers upon subcutane-
ous transplantation into NOD/SCID/gcnull mice (Figure 1F).
Two further clones named CD45.1(1.1) and CD45.1(10.4)
iPSC were characterized for ESC-like morphology, alkaline
phosphatase activity, and expression of SSEA-1 as well as
NANOG, SOX2, and OCT4 expression (Figures S1A–S1F).
Differentiation of CD45.1iPSCs into M4
Differentiation studies of murine CD45.1iPSCs into M4
utilized an embryoid body (EB)-based protocol previously
established by our group and employing the cytokines
murine stem cell factor (mSCF) and murine inter-
leukin-3 (mIL-3) to drive hematopoietic differentiation and
generate immature CD41+ hematopoietic stem/progenitor
cells (Pfaff et al., 2012). For the current studies, the protocol
was modified to perform suspension cultures of EBs on an
orbital shaker, and to achieve terminal M4 differentiation
insecondary cultures employingmacrophage colony-stimu-
lating factor (M-CSF) treatment of CD41+ cells from day 8
onward (Figures 2A and 2B). Secondary cultures were main-
tained for at least another 10 days, at which time point cells
displayed plastic adherence and M4-typical morphology.
Following this protocol, expression of the early hematopoi-
etic marker CD41, traditionally used to define a primitive
hematopoietic population in the aorta-gonad-mesonephros
region of mice (Rybtsov et al., 2011), was detected in 25%–
70% of cells on day 8 for the CD45.1(10.3) iPSC clone. Of
note, most of CD41+ cells displayed classical hematopoietic
progenitor (blast-like) morphology on May-Gru¨nwald/
Giemsa-stained cytospins (Figure 2C). When secondary
cultures set up from these CD41+ cells were harvested after
another 10–20 days of differentiation in the presence of
M-CSF, an approximately 10-fold increase in cell numbers
was observed (Figure 2D). M4 characteristics of almost all
cells (>95% purity) were verified by typical, spread-out
morphology upon bright-field microscopy and strong
adherence to non-tissue culture-treated plates as well as a
classical M4 phenotype on May-Gru¨nwald/Giemsa-stained
cytospins resembling BMlin-M4 used as controls (Figures
2E and 2F). CD45.1(10.3) iPSC-M4 displayed the classical
M4 marker F4/80 in association with the myeloid marker
CD11b on their surface (Figures 2G and 2H).Moreover, cells
expressed high levels of the pan-hematopoietic markerStem Cell Reports j Vol. 7 j 292–305 j August 9, 2016 293
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Figure 1. Characterization of iPSCs Derived from CD45.1 C57BL/6 Mice
(A and B) ESC-like morphology in bright-field images (A) and positive alkaline phosphatase staining of CD45.1(10.3) iPSCs (B). Scale bar,
200 mm.
(C and D) NANOG, OCT4, and SOX2 expression by immunofluorescence staining (C) (scale bar, 50 mm) as well as by (D) qRT-PCR using murine
specific primers (independent experiments, n = 3, mean ± SD). ns, not significant compared with ESCs, two-way ANOVA.
(E) Representative flow cytometry plot revealing expression of the SSEA-1 surface marker (unstained, orange filled; SSEA-1 stained
CD45.1(10.3) iPSCs, green).
(F) Representative pictures of CD45.1(10.3) iPSC-derived teratomas containing tissues of all three embryonic germ layers. Scale bar, 50 mm
for ectoderm and endoderm; 100 mm for mesoderm.CD45, here specifically CD45.1 (Ly5.1), whereas markers
of alternative hematopoietic lineages such as Gr-1, CD11c,
CD3, and B220 were low or absent.
To assess the robustness of our differentiation pro-
tocol, we compared hematopoietic differentiation of the
CD45.1(10.3) iPSCwild-type control clonewith two further
CD45.1 iPSC clones (clones 1.1 and 10.4), two iPSC clones
derived from BMlin cells (lin-7 and -9) as well as a murine
ESC clone (OG2 ESCs). Of note, for all these clones our pro-
tocol yielded reliable macrophage differentiation, which
was confirmed by classical macrophagemorphology in cul-
tures and on May-Gru¨nwald/Giemsa-stained cytospins
(Figures S2A–S2E) as well as a CD45+, CD11b+, and F4/80+
surface phenotype associatedwith lowor absent expression
of other hematopoietic lineage markers such as CD14,
CD11c,Gr-1, CD3, B220, andCD41 (Figures S2F–S2J).How-
ever, considerable clone-specific differences were detected
with regard to thenumbers ofCD41+ cells andmacrophages
obtained for a given iPSC input (Figure S3).
When compared with M4 derived from different in vivo
sources (blood, peritoneal cavity, bronchoalveolar lavage
fluid) or generated in vitro from BMlin cells, iPSCs-M4
[here represented by cells derived from clone CD45.1(10.3)
iPSC] most closely resembled their in vitro-generated coun-294 Stem Cell Reports j Vol. 7 j 292–305 j August 9, 2016terparts (Table 1). While all cells analyzed expressed high
levels of CD45 and were positive for the common M4
markers F4/80, in accordance with the current literature,
CD11b was expressed highest onmonocytes and peritoneal
M4, and CD11c and SIGLEC-F was detected primarily on
alveolar M4 (Feng and Mao, 2012; Hussell and Bell, 2014).
In addition, we analyzed the functionality of our
CD45.1(10.3) iPSC-M4with regard to the release of chemo-
kines in response to extracellular stimuli as well as
their phagocytic capacity. In these studies, CD45.1(10.3)
iPSC-M4 produced chemokines typically secreted by M4
uponbacterial endotoxin stimulation andmediating crucial
functions in the inflammatory response such as monocyte
chemoattractantprotein1 (MCP-1),MCP-3,macrophage in-
flammatory protein 1b (MIP-1b), and RANTES. Chemokine
levels induced in CD45.1(10.3) iPSC-M4 in response to
lipopolysaccharide (LPS) stimulation were similar to the
levels induced in their BMlin cell-derived counterparts (Fig-
ure 3A). To assess the phagocytic capacity of CD45.1(10.3)
iPSC-M4, we tested their ability to internalize yeasts using
the number of ingested yeast particles per cell as a readout.
These studies also demonstrated similar functionality of
CD45.1iPSC- and BMlin-M4 (Figure 3B). Of note, imma-
ture cells such as iPSCs were not able to take up yeast cells.
AB
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Figure 2. Differentiation of iPSCs into M4
(A) Schematic representation of the three step EB-based protocol employed for hematopoietic differentiation. (1) embryoid bodies (EBs)
are formed for 8 days in the presence of 10 ng/ml IL-3 with 30 ng/ml SCF added from day 5 onward; (2) EBs are dissociated to single cells
and CD41+ cells are isolated by fluorescence-activated cell sorting; and (3) terminal differentiation is achieved by 10–15 days of adherent
culture in the presence of 30% M-CSF containing supernatant (L929 cells).
(B) Representative picture of EBs at day 8. Scale bar, 500 mm.
(legend continued on next page)
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Table 1. Marker Expression of Different Monocyte/Macrophage Populations
In Vivo Derived Cell Types In Vitro Derived Cell Types
Blood Monocytes Peritoneal M4 Alveolar M4 BMlin-M4 CD45.1iPSC M4
CD45 +++ +++ ++ ++ +++
CD11b ++ +++ – + +
CD11c + – ++ + +
CD200R – + + ++ +
F4/80 + ++ + +++ +
SIGLEC-F – – + + +
Mean fluorescence intensities (MFIs) lower than 33 102 are – (no expression), MFIs between 33 102 and 104 are + (low expression), MFIs between 104 and
5 3 104 are ++ (intermediate expression), and MFIs greater than 5 3 104 are +++ (high expression).To rule out the presence of residual undifferentiated
iPSCs that could give rise to teratomas and thus may
be problematic in future in vivo experiments employing
our iPSC-M4, we performed transplant experiments in
immunodeficient NSGmice. In these studies, no teratomas
were detected 5 weeks after subcutaneous injection of 3 3
106 CD45.1(10.3) iPSC-M4 into the flanks or 4 weeks after
intratracheal application of 1.8–2.3 3 106 CD45.1(10.3)
iPSC-M4 into the airways of NSG mice (both n = 2). How-
ever, we did detect a substantial population of donor-
derived cells in the lungs of recipient animals following
the intratracheal transplant procedure.
Moreover, to further assess the feasibility to perform
in vivo studies with our iPSC-M4 we investigated the pul-
monary engraftment and survival of CD45.1 iPSC(10.3)-
M4 in our murine herPAP disease model 8 weeks following
intratracheal application of 4 3 106 cells (n = 1). In this
experiment the presence of a substantial population of
CD45.1+ donor type (i.e., CD45.1(10.3) iPSC-M4) cells
was detected, contributing 3.1% and 1.2% to the respective
populations of the bronchoalveolar fluid and the lungs
(Figures S4A–S4C).
Generation and Hematopoietic Differentiation of
Murine PAP-Specific iPSCs from Csf2rb/ Mice
As a next step, we wanted to investigate the feasibility of
our in vitro differentiation system to serve as a model for
rare congenital diseases associated with M4 malfunction.
In this regard, disease-specific miPAP were generated from
BMlin cells of Csf2rb/ mice (Nishinakamura et al.,(C) Flow cytometric analysis of CD41 expression on day 8 and represen
cells. Scale bar, 50 mm.
(D) Approximately 10-fold increase in cell number during differentiat
(E and F) Representative pictures of (E) BMlin-M4 and (F) CD45.1 i
spins. Scale bars, 100 mm and 20 mm.
(G and H) Exemplary flow cytometry plots for expression of surface ma
and B220 on BMlin-M4 (G) and CD45.1iPSC-M4 (H).
296 Stem Cell Reports j Vol. 7 j 292–305 j August 9, 20161995), a mouse strain that reliably recapitulates the dis-
ease phenotype of herPAP patients (Happle et al., 2014).
Two clones (miPAP1 and miPAP2) were established that
showed characteristic morphology (Figures 4A and S5A)
and pluripotency features such as alkaline phosphatase
activity, endogenous expression of the pluripotency-asso-
ciated transcription factors Oct4 and Nanog, SSEA1 expres-
sion on the cell surface, and the ability to form teratomas
in immunodeficient mice (Figures 4B–4F and S5B–S5F).
The knockout of the GM-CSF receptor b-chain gene
(Csf2rb) in these clones was confirmed by PCR on
genomic DNA (Figure 4G). When we subjected these cells
to our differentiation protocol, we again obtained typical
EBs giving rise to CD41+ cells on day 8 of differentiation
(Figures 5A, 5B, S5G, and S5H). In the presence of
M-CSF these CD41+ cells could be further differentiated
to M4 with classical morphology and an F4/80+ CD11b+
CD45.2+ surface phenotype (Figures 5C, 5D, and S5I–
S5K). In this regard, the data mimicked those obtained
with the different CD45.1 iPSCs clones generated from
healthy cells. In quantitative terms, however, efficacy of
macrophage differentiation for the two miPAP clones
was rather low, resulting in a markedly (at least 1–2 log)
decreased macrophage output when compared with input
iPSCs.
miPAP-Derived Macrophages Display Perturbed
GM-CSF-Mediated Functionalities
To investigate whether our differentiation procedure was
able to recapitulate the defect in the GM-CSF receptortative picture of May-Gru¨nwald/Giemsa-stained cytospins of CD41+
ion (independent experiments, n = 3, mean ± SD).
PSC-M4 in bright-field and in May-Gru¨nwald/Giemsa-stained cyto-
rkers F4/80, CD11b, CD14, CD11c, Gr-1, CD45.1, CD45.2, CD41, CD3,
AB
Figure 3. Functional Characterization of iPSC-M4
(A) Secretion of monocyte chemoattractant protein 1 (MCP-1), -3 (MCP-3), macrophage inflammatory protein 1b (MIP-1b), and RANTES
upon stimulation of BMlin- and CD45.1(10.3) iPSC-M4 with LPS (technical replicates n = 2, mean ± SD).
(B) Phagocytosis of yeast particles by undifferentiated iPSCs, BMlin-, and CD45.1iPSC-M4 (technical replicates n = 2, mean ± SD).functionality typical for herPAP, we first tested the capacity
of CD41+ progenitors generated from miPAPs to form col-
onies in the presence of GM-CSF. Here, CD41+ cells derived
from miPAP clones did not form colonies in the presence
of GM-CSF only (Figure 6A). This was in contrast to
CD45.1(10.3) iPSC-derived CD41+ cells, which gave rise
to GM-CSF-dependent white colonies. Of note, control
cultures with a combination of IL-3, SCF, IL-6, erythropoi-
etin, granulocyte colony-stimulating factor (G-CSF), and
M-CSF (complete medium) served as positive controls for
both CD45.1iPSC- and miPAP-derived CD41+ cells. Similar
results were obtained when miPAP-derived terminally
differentiatedM4were evaluated (miPAP-M4).When these
cells were tested for the ability to clear GM-CSF from
the medium, the cytokine concentration remained con-
stant in the supernatant of miPAP-M4, whereas healthy
CD45.1(10.3) iPSC-M4 reduced GM-CSF concentrations
over a time period of 30 hr (Figure 6B). Moreover, to study
signaling from the GM-CSF receptor in our model in more
detail, we evaluated the activation of downstream targets.
Here we focused on the phosphorylation state of the tran-
scription factor STAT5, one of the most important down-
stream targets of GM-CSF receptor signaling. As depicted
for an exemplary experiment (Figure 6C) and summarized
in Figures 6D and 6A, significant upregulation of the
phosphoSTAT5 signal was detected in M4 derived from
CD45.1(10.3) iPSCs employed as a positive control. In
contrast, perturbed upregulation was detectable in M4derived from the two miPAP clones, again underscoring
the suitability of our in vitro differentiation system to
model the defective M4 functionality associated with
herPAP.DISCUSSION
Extending on previously established protocols initially
designed to generate CD41+ hematopoietic progenitor cells
(Ma et al., 2008; Pfaff et al., 2012), we here describe a robust
and highly reproducible hematopoietic differentiation
protocol allowing for the efficient generation of mature
and functional M4 from murine iPSC and ESC sources.
The M4 obtained recapitulate the morphology, surface
phenotype, and functionality of their counterparts differ-
entiated in vitro from BMlin hematopoietic progenitor
cells. Differentiation was associated with profound cell
expansion, as in our hands up to 1.5 3 105 M4 were
generated from a starting population of 1,000 iPSCs from
our reference CD45.1(10.3) iPSC clone. This efficacy ap-
pears to compare favorably with data from other groups,
including a recently published study investigating the
generation of AM-typemacrophages from iPSCs sources re-
porting an approximately one-to-one ratio of starting iPSCs
to AM 4 generated (Litvack et al., 2016), although a direct
comparison turns out to be difficult because of different
starting populations as well as the diversity of methodsStem Cell Reports j Vol. 7 j 292–305 j August 9, 2016 297
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Figure 4. Characterization of Disease-Specific iPSCs from Csf2rb/ Mice
(A and B) ESC-like morphology in bright-field images (A) and positive alkaline phosphatase staining of miPAP1 iPSCs (B). Scale bar,
200 mm.
(C) NANOG, OCT4, and SOX2 expression by immunofluorescence staining (C; scale bar, 50 mm) as well as by (D) qRT-PCR using murine-
specific primers (independent experiments, n = 3, mean ± SD). ns, not significant compared with ESCs, two-way ANOVA.
(E) Representative flow cytometry plot revealing expression of the SSEA-1 surface marker.
(F) Representative pictures of miPAP1-derived teratomas containing tissues of all three embryonic germ layers. Scale bar, 50 mm for
ectoderm and endoderm; 100 mm for mesoderm.
(G) Scheme and gel electrophoresis of PCR on genomic DNA for genotyping miPAP clones.employed (Neri et al., 2015; Senju et al., 2009; Zhuang
et al., 2012). However, we observed marked differences
in the efficacy ofM4 generationwhenwe investigated a va-
riety of iPSC and ESC clones. While some of these clones
performed even better than the CD45.1(10.3) iPSC refer-
ence clone, in particular our disease-specific miPAP clones
demonstrated a markedly reduced output of CD41+ cells
as well as macrophages. Most likely this can be explained
by the lack of the common GM-CSF receptor b chain (bc)
in the miPAP clones, as the b chain also is involved in con-
ventional IL-3 signaling and our differentiation protocol
primarily employs the cytokines SCF and IL-3 to drive he-
matopoietic specification. Even though murine cells have
an additional ‘‘private’’ IL-3 signal transduction chain inde-
pendent from the common GM-SCF/IL-3/IL-5 receptor
complex (Nishinakamura et al., 1995), the lack of the b
chain may contribute to the reduced expansion efficacy298 Stem Cell Reports j Vol. 7 j 292–305 j August 9, 2016observed for the miPAP clones. On the other hand, these
differences also may reflect the considerable genetic and
epigenetic differences present between individual iPSC
and ESC clones and sometimes even between different
passage cells of the same clone (Liang and Zhang, 2013).
We believe that our iPSC-M4 hold considerable potential
for disease modeling, in particular for disease entities
associated with M4 malfunction. Therefore, as a proof of
concept, we generated herPAP-specific iPSCs from mice
deficient for the GM-CSF receptor bc chain, differentiated
these cells into M4, and analyzed GM-CSF-dependent
functions in these cells. As previously described for primary
M4 of these mice including alveolar M4 (Happle et al.,
2014; Kleff et al., 2008), these in vitro studies recapitu-
lated the characteristic defects in the GM-CSF response of
herPAP patient-derived M4. Specifically, defects in GM-
CSF-driven colony formation and terminal differentiation
Figure 5. Differentiation of miPAP1 into M4
(A and B) Representative picture of (A) bright-field EBs at day 8 of differentiation (scale bar, 500 mm) and (B) flow cytometric analysis of
CD41 expression.
(C) Representative pictures of (upper picture; scale bar, 100 mm) bright-field microscopy and (lower picture; scale bar, 20 mm)
May-Gru¨nwald/Giemsa-stained cytospins of miPAP1-M4.
(D) Flow cytometric analysis of surface marker expression (data for F4/80, CD11b, CD14, CD11c, Gr-1, CD45.1, CD45.2, CD41, CD3, and
B220).capacity, GM-CSF uptake, as well as the phosphorylation of
STAT-5 downstream of the GM-CSF receptor upon GM-CSF
stimulation were demonstrated. Given the extreme rarity
of CSF2RB-deficient PAP patients (Suzuki et al., 2011) and
the ensuing lack of primary patient material for research
in this disease entity, the murine iPSC-based in vitro her-
PAP model presented here may have immediate relevance.
Provided that the number of macrophages obtained from
our miPAP clones can be increased, the model presented
here may be employed for pathophysiologic studies as
well as for drug testing. An example would be a screen for
pharmaceutical compounds potentially ameliorating the
PAP phenotype such as inducers of the transcription factor
PU.1 or the nuclear receptor PPARg (Malur et al., 2011; Shi-
bata et al., 2001).
Recently, profound therapeutic efficacy of intratra-
cheally transplanted bone marrow-derived M4 has been
demonstrated in two murine disease models of herPAP,
indicating a therapeutic potential also of iPSC-derived
M4 (Happle et al., 2014; Suzuki et al., 2014a). In this
context genetically repaired human herPAP patient-spe-cific iPSCs lines already have been generated, and func-
tional M4 derived from these lines potentially represent
an autologous cell source for herPAP therapy (Lachmann
et al., 2014; Suzuki et al., 2014b).Moreover, in amurine dis-
ease model of adenosine deaminase deficiency, therapeutic
benefit has been demonstrated following the intrapulmo-
nary administration of iPSC-derived AM-like cells with a
characteristic F4/80+ CD11c+, SIGLEC-F+ surface pheno-
type and an AM-typical gene-expression pattern (Litvack
et al., 2016). On this background pulmonary macrophage
transfer of autologous gene-corrected iPSC-M4 may repre-
sent an innovative therapeutic option for other disease en-
tities associated with malfunction of AMs such as chronic
obstructive pulmonary disease (Hodge et al., 2003), bron-
chopulmonary dysplasia (Blackwell et al., 2011), or cystic
fibrosis (Bruscia et al., 2009; Di et al., 2006). Moreover,
site-specific transplantation of iPSC-M4 into organs such
as the liver or the brain may turn out to be relevant also
for other diseases associated with M4 malfunction such
as heme oxygenase-1 deficiency (Kovtunovych et al.,
2014) or adrenoleukodystrophy (Okamura et al., 2009).Stem Cell Reports j Vol. 7 j 292–305 j August 9, 2016 299
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Figure 6. Disease Modeling of herPAP Using miPAP iPSCs
(A) Number of CD41+ progenitor-derived colonies in methylcellulose-based clonogenic assays employing complete (IL-6, erythropoietin,
SCF, IL-3, and supplemented with 20 ng/ml human G-CSF + 20 ng/ml murine GM-CSF) or basic medium (50 ng/ml murine GM-CSF only;
independent experiments, n = 3 miPAP1 and 2, n = 2 CD45.1 iPSC, mean ± SD) and representative pictures of colonies. Scale bars, 500 mm.
(B) GM-CSF clearance assay comparing miPAP-M4 with CD45.1(10.3) iPSC-M4, BMlin-M4, and no cells incubated with 2 ng/ml GM-CSF:
at indicated time points (0, 4, 10, 24, and 30 hr) GM-CSF concentrations in supernatants were analyzed by ELISA, normalized to 0 hr
(independent experiments, n = 3 BMlin and CD45.1 iPSC, n = 2 miPAP1 and 2, mean ± SD).
(C and D) Flow cytometry plots of STAT5 phosphorylation levels upon stimulation with mGM-CSF (C) and (D) summary of mean fluorescence
intensity (MFI) data (independent experiments, n = 3 BMlin and CD45.1 iPSC, n = 2 miPAP1 and 2, mean ± SD).
ns, not significant; **p% 0.01, ***p% 0.001, ****p% 0.0001, two-way ANOVA.
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In summary, we here describe a highly robust and effi-
cient protocol for the generation of murine iPSC-M4,
which phenotypically and functionally show high similar-
ity to their primary M4 counterparts. Moreover, we em-
ployed this protocol to obtain disease-specific iPSC-M4
from herPAP mice and recapitulated in vitro the hallmark
M4 phenotype of this disorder. Thus, this study introduces
a unique tool for the study of M4 and iPSC-M4 biology in
healthy and disease contexts, provides an in vitro disease
model to study CSF2RB-deficient herPAP, and may eventu-
ally contribute a platformuponwhich to develop advanced
therapeutic approaches in herPAP or other severe M4-
related disease entities.EXPERIMENTAL PROCEDURES
Bone Marrow Isolation and Lineage Depletion
Femurs and tibias of wild-type B6.SJL-PtprcaPepcb/BoyJ (CD45.1
BL/6) and C57BL/6 Csf2rb/ (Nishinakamura et al., 1995) mice
were flushed with PBS supplemented with 2% heat-inactivated
fetal calf serum (FCS; Millipore) and 2 mM EDTA (Sigma). Subse-
quently, bone marrow lineage-negative cells (BMlin) were puri-
fied using immunomagnetic separation (mouse lineage depletion
kit, Miltenyi Biotech) as recommended by the manufacturer.
BMlin cells were maintained in serum-free STIF medium as
described previously (Brennig et al., 2015).
Lentiviral Particles Production
Production and titration of third-generation self-inactivating (SIN)
lentiviral vectors was performed as previously described (Lach-
mann et al., 2015) and titers of 105–106 TU/ml were achieved.
Reprogramming of BMlin Cells
5 3 105 BMlin cells were transduced with an established third--
generation monocistronic SIN lentiviral vector containing the
four pluripotency factors OCT4, SOX2, KLF4, and c-MYC ex-
pressed form the viral promoter SFFV (Kuehle et al., 2014). Trans-
duction was performed on retronectin-coated plates (Takara Bio)
according to the manufacturer’s instructions. Subsequently, cells
were cultured in STIF medium supplemented with 2 mM valproic
acid (Sanofi). After 7 days, cells were moved onto C3Hmurine em-
bryonic fibroblasts (MEF), and an equal amount of mESC medium
(see below) containing 103 U/ml leukemia inhibitory factor (LIF)
(kindly provided by the Institute of Technical Chemistry, Hann-
over Medical School) was added to the culture at this time point
and completely substituted after 14 days. Approximately 21 days
later, the first ESC-like colonies were picked from the original plate
and single colonies were trypsinized and expanded on C3H MEF.
Murine iPSC Cell Culture
Murine ESCs and iPSCs (OG2 ESCs [Szabo´ et al., 2002], CD45.1
iPSCs clones 10.3, 1.1, and 10.4, miPAP 1 and 2, and iPSC lin-7
and lin-9 [Pfaff et al., 2012]) were maintained in Knockout
DMEM medium (Thermo Fisher Scientific) supplemented with
15% FCS, 1 mM penicillin-streptomycin, 1 mM L-glutamine,0.05 mM b-mercaptoethanol, 1 mM non-essential amino acids,
and 103U/ml LIF onC3HMEF as previously described (Ackermann
et al., 2014).
Immunofluorescence and Alkaline Phosphatase
Staining
Cells were plated in a 24-well plate at low confluence, fixed in 4%
paraformaldehyde (Sigma-Aldrich), permeabilized in 0.7% Triton
X-100 (Carl Roth), and blocked with the appropriate serum.
Nuclei were stained with DAPI (dilution 1:4,000) for 45 min and
primary as well as subsequent secondary antibodies were incu-
bated for 1 hr at room temperature. Primary antibodies: anti-
hOCT3/4 (mouse monoclonal antibody [mAb] C-10, sc-5279,
Santa Cruz Biotechnology, dilution 1:250), anti-hSOX2 (goat pri-
mary antibody [pAb] Y-17, sc17320, Santa Cruz, dilution 1:100),
and anti-NANOG (Rb pAb, ab80892, Abcam, dilution 1:500).
Secondary antibodies: donkey anti-mouse immunoglobulin G
(IgG)-Alexa 488, rabbit anti-mouse IgG-Alexa546, goat anti-rabbit
IgG-Alexa 488 (715-545-150/711-545-152, all Jackson Immune
Research Europe, dilution 1:400). Cells were stained with the
Alkaline Phosphatase Detection Kit (Millipore) according to the
manufacturer’s instructions.
qRT-PCR
Total RNA was isolated using TRIzol-chloroform and subsequently
treated with DNaseI (DNase I, RNase-free [1 U/ml]; Thermo Fisher
Scientific). RNA was reverse transcribed using RevertAid reverse
transcriptase and random hexamer primers (both Thermo Fisher
Scientific). 100 ng of cDNAwas used as input for quantification us-
ing the following TaqMan primers: mOct4 (Mm00658129_gH),
mSox2 (Mm00488369), andmNanog (Mm02384862_g1) (Thermo
Fischer Scientific). Real-time PCR was performed on a StepOnePlus
thermocycler (Applied Biosystems).
Teratoma Formation
Undifferentiated iPSCs (2 3 106) or CD45.1(10.3) iPSC-M4 (3 3
106) were injected subcutaneously into the right or left flank of
NOD/SCID/gcnull (NSG) mice. Two to five weeks after injection,
tumors derived from undifferentiated iPSCs were palpable and
the mice were euthanized. Isolated teratomas were fixed in 4%
formaldehyde and paraffin sections were stained with H&E for
histologic analysis. In addition, 1.8–2.3 3 106 CD45.1(10.3)
iPSC-derived macrophages were transplanted intratracheally into
NSG mice.
M4 Differentiation of iPSCs
iPSC-derived M4were generated using a modified version of a pre-
viously established protocol (Pfaff et al., 2012). In brief, iPSCs were
passaged on a gelatinized flask before undergoing single-cell-based
EB formation. 5,000–30,000 cells/mlwere seeded in differentiation
medium (IMDM medium; Thermo Fisher Scientific) with 15%
pre-tested FCS (ES-Cult, Stem Cell Technologies), 1 mM peni-
cillin-streptomycin, 1 mM L-glutamine, 50 ng/ml ascorbic acid
(Sigma-Aldrich), and 150 mM monothioglycerol (Sigma-Aldrich)
in a 10-cm suspension dish and grown for 8 days on a rotator
shaker (100 rpm). At day 5, medium was supplemented with
10 ng/ml murine IL-3 and 30 ng/ml mSCF (Peprotech). AfterStem Cell Reports j Vol. 7 j 292–305 j August 9, 2016 301
8 days EBs were dissociated in collagenase IV (Life Technologies)
and CD41-expressing cells were isolated via fluorescence-activated
cell sorting. The purified populationwas further differentiated into
M4 for 10–20 days in RPMI medium (Thermo Fisher Scientific)
supplemented with 10% FCS, 1 mM L-glutamine, 1 mM peni-
cillin-streptomycin, and 30% supernatant of L929 producer cells
as a source of M-CSF (Zanoni et al., 2009).
Intrapulmonary Transplantation of CD45.1(10.3)
iPSC-M4 into Csf2rb/ and NSG Mice
Csf2rb-/-, NSG and B6.SJL-Ptprca-Pep3b/BoyJ (CD45.1) donor mice
were obtained from the central animal facility of Hannover Medi-
cal School. Mice were kept under specific pathogen free conditions
and had free access to food andwater. All animal experiments were
approved by the Lower Saxony State animal welfare committee
and performed according to their guidelines. CD45.1(10.3) iPSC-
M4 (4 3 106) were resuspended in a 60-ml volume and instilled
through the trachea. Eight weeks after transplantation into
Csf2rb/ mice bronchoalveolar lavage fluid, lungs, bone marrow,
lymph nodes, spleen, and liver were isolated, and flow cytometry
analysis as well as genomic DNA isolation was performed.
Similarly, 4 weeks after intratracheal administration of 1.8–2.33
106 CD45.1(10.3) iPSC-M4 into NSGmice, genomic DNAwas iso-
lated, and the presence of CD45.1(10.3) iPSC-derived progenies in
the lung, liver, spleen, bone marrow, and lymph nodes was inves-
tigated by PCR.
Cytospin
M4 or CD41+ cells (20,000–40,000) were spun on glass slides at
600 3 g for 7 min and then stained according to the May-Gru¨n-
wald/Giemsa staining protocol.
Flow Cytometry
For detection of surface markers and intracellular proteins, cells
were harvested after trypsin treatment and resuspended in PBS
supplemented with 2% FCS. Cells were pretreated with CD16/
CD32 Fc-Block (eBioscience) for 20 min at 4C. The following
antibodies were used in concentrations according to instructions:
SSEA-1-APC (51-8813-71), CD41-APC (17-0411-82), F4/80-APC
(17-4801-80), CD11b-PE/eFluor 450 (12-0112-82/48-0112),
CD14-FITC (11-0141-81), CD11c-PE-Cy7 (11-0141-81), Gr-1-
eFluor450 (48-5931-82), CD45.1-PE-Cy7/APC (25-0453-81/17-
0453), CD45.2-PE (12-0454-81), CD3-FITC (11-0031-81), B220-
eFluor450 (48-0452-82), CD45-PE-Cy7/eFluor450 (25-0451-82/
48-0451), CD200R-APC (17-5201), CD68-PE-Cy7 (25-0681) (all
from eBioscience), SIGLEC-F-PE (552126, Becton Dickinson),
Phospho-STAT5 (Tyr694) (C71E5) rabbit mAb (Alexa Fluor 647
conjugate) (9365, Cell Signaling), or Anti-Human/Mouse phos-
pho-STAT5 (Y694) APC (17-9010, eBioscience). Fluorescence was
measured using a BD FACSCalibur or BD LSR II and Fc-Block
treated unstained sample was used as negative control.
Yeast Phagocytosis Assay
For testing of phagocytic activity, BMlin-derived M4
(BMlin-M4), iPSCs, and CD45.1iPSC-derived M4 (iPSC-M4)
were incubated with OD660:0,1 heat-inactivated baker’s yeast
labeled with 10 mg/ml Kongo red in RPMI-based culture medium.302 Stem Cell Reports j Vol. 7 j 292–305 j August 9, 2016At indicated time points, the number of yeasts per cells was
counted using a binocular microscope.
Chemokine Release Assay
M4/well (105) were seeded overnight in tissue-culture-treated
24-well plates and stimulated with 1 mg/ml LPS (Sigma-Aldrich).
Chemokine concentration was measured after 0, 24, and 48 hr us-
ing the Chemokines 6plex FlowCytomixMultiplex Kit (BMS821FF,
eBioscience).
PCR on Genomic DNA
Genomic DNA (gDNA) was isolated from tissues or iPSCs using
the Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. Detection of the
neomycin resistance gene was performed using 100 mg of gDNA
and primers (50-GCGTTGGCTACCCGTGATAT-30; 30-GGTCTCCC
AGACAAGCTTGAACC-50) as described previously (Nishinaka-
mura et al., 1995).
Clonogenic Progenitor Assay
Hematopoietic CD41+ progenitor cells obtained from iPSC dif-
ferentiation (8 days after start of EB culture) were seeded at a
concentration of 20,000–50,000/ml in basic and completemethyl-
cellulose medium (HSC006 with no cytokines added and HSC007
containing IL-6, erythropoietin, SCF, and IL-3, respectively; R&D
Systems). HSC007 was additionally supplemented with 20 ng/ml
human G-CSF and 20 ng/ml murine M-CSF, while HSC006 was
supplemented with 50 ng/ml murine GM-CSF (all Peprotech).
Cells were grown for 7–10 days and colonies composed of more
than 50 cells were counted.
ELISA
Concentration of GM-CSF was evaluated by ELISA following the
manufacturer’s instructions (Mouse GM-CSF ELISA Ready-SET-
Go!, Affymetrix eBioscience).
Statistics
All graphs were created and statistical analysis performed with
Prism V6 (GraphPad). One-way or two-way ANOVA testing was
applied. Significance is indicated with asterisks (*p < 0.05; **p <
0.01; ***p < 0.001; ****p < 0.0001), and specific tests applied are
mentioned in each figure legend.
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